Current Research into Cures for Type-1 Diabetes

Unfortunately, this is bad news.  But here it is: Canakinumab and Anakinra Both Fail Phase-II Trials in Honeymooners Canakinumab (br...

Canakinumab Completes Enrollment Canakinumab is a monoclonal antibody, which is designed to lower inflammation.  It targets IL-1β (interl...

Polyclonal Tregs Starts a Phase-I Clinical Trail This one is a little complex.  The body's immune system includes T-regulatory cells, ...

This is a "hat trick" of new drugs preparing to enter phase-II trials for type-1 diabetes.  Each one of these has started the p...